In this portion of our Pharmaceutical Executive Video Interviews, Lowenstein Sandler’s Jim Sheehan, Chair of the FDA’s Regulatory Affairs Division, discusses the top legal and regulatory concerns investors should consider when funding companies developing or marketing GLP-1 drugs.
Key GLP-1 legal and regulatory concerns for investors
Leave a comment
